Electromed, Inc.

Electromed, Inc.

ELMD
Electromed, Inc.US flagNew York Stock Exchange Arca
28.00
USD
+0.39
- -
231.84MMarket Cap
Electromed, Inc.
ELMD
(New York Stock Exchange Arca)

Recent

price

28.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
2.43
2.41
1.86
1.91
2.39
2.83
3.17
3.45
3.77
3.86
4.17
4.92
5.68
6.39
7.57
- -
8.93
Revenue per Share
0.14
0.02
-0.16
-0.16
0.13
0.27
0.27
0.22
0.24
0.5
0.28
0.27
0.37
0.6
0.89
- -
1.37
Basic EPS, GAAP
-0.33
-0.25
0.1
0.14
0.27
0.2
0.06
0.23
0.14
0.38
0.31
-0.08
0.16
1.06
1.35
- -
1.17
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.82
1.86
1.72
1.57
1.71
2
2.32
2.73
3.06
3.53
3.8
4.03
4.4
5.16
5.18
6.45
6.45
Book Value per Share
1.66
1.71
1.58
1.44
1.59
1.89
2.23
2.65
2.99
3.46
3.72
3.96
4.33
5.08
5.02
6.27
6.27
Tangible Book Value per Share
8
8
8
8
8
8
8
8
8
8
9
8
8
9
8
- -
8
Basic Weighted Avg Shares
19
20
15
15
19
23
26
28
31
32
36
42
48
55
64
74
74
Sales/Revenue/Turnover
9.84
3.11
-12.1
-4.78
6.75
13.52
13.8
9.58
9.04
15.76
8.78
7.13
8.34
12.03
15.09
18.82
18.82
Operating Margin (%)
- -
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Depreciation Expense
1
- -
-1
-1
1
2
2
2
2
4
2
2
3
5
8
11
11
Net Income, GAAP
37.11
57.36
- -
- -
10.78
27.28
36.65
32.98
32.19
20.58
25.42
23.09
22.52
26.81
26.71
21.3
21.3
Effective Tax Rate (%)
5.55
0.96
-8.8
-8.32
5.63
9.62
8.62
6.47
6.33
12.81
6.61
5.53
6.59
9.41
11.78
15.32
15.32
Profit Margin (%)
12
12
10
9
10
13
16
18
21
25
27
27
30
36
35
45
45
Working Capital
2
1
1
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
15
15
14
13
14
16
19
23
26
30
32
34
38
45
43
54
54
Total Equity
7.82
1.4
- -
- -
8
13.8
11.95
8.19
7.67
14.47
7.45
6.84
8.61
11.64
16.1
22.5
22.5
Return on Invested Capital (%)
7.84
1.42
- -
- -
8.01
13.87
12.03
8.34
8.01
14.86
7.54
6.92
8.81
12.53
17.18
23.26
23.26
Return on Capital (%)
9.52
1.25
-9.17
-9.67
8.2
14.61
12.59
8.79
8.2
14.86
7.54
6.92
8.81
12.53
17.18
23.26
23.26
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
241
194
354

Working Capital

FRC

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
46
50
57
Cash, Cash Equivalents & STI
14
17
20
Accounts Receivable, Net
26
28
30
Inventories
3
3
4
Total Current Liabilities
9
10
12
Payables & Accruals
4
4
4
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.95%
11.17%
24.93%
Free Cash Flow
49.89%
36.44%
-15.17%
Net Income, GAAP
25.18%
38.78%
49.94%
Sales/Revenue/Turnover
12.43%
15.59%
15.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12
14
14
15
55
2025
15
16
16
17
64
2026
17
19
19
19
74

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.2
0.17
- -
0.6
2025
0.17
0.23
0.22
0.26
0.89
2026
0.26
0.33
0.37
0.41
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Electromed, Inc. develops, manufactures, markets, and sells medical devices that provide airway clearance therapy, primarily through its flagship product, the SmartVest Airway Clearance System. The SmartVest Systems utilize High Frequency Chest Wall Oscillation (HFCWO) technology to assist patients with compromised pulmonary function by facilitating mucus clearance. The company’s product portfolio includes the SmartVest SQL System, SmartVest Clearway System for inpatient hospital use, and single-patient-use SmartVest and SmartVest Wrap products. These devices are marketed to hospitals, home health care providers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and directly to patients, primarily in the United States, with distribution through both direct sales and home medical equipment distributors. Founded in 1992 and headquartered in New Prague, Minnesota, Electromed targets patients with chronic respiratory conditions such as bronchiectasis, cystic fibrosis, and neuromuscular disorders. The company serves healthcare providers and patients by incorporating personalized therapy options, including recent expansions in SmartVest garment and generator color options to improve patient satisfaction and adherence. Recent major developments include Electromed’s strategic expansion of distribution channels via partnerships with national and regional home medical equipment distributors, enhancing access to the SmartVest in the U.S. home care market. In 2024, Electromed launched the SmartVest Clearway Airway Clearance System designed specifically for hospital inpatient use. The company also authorized a $10 million stock repurchase program in 2025, reflecting strong operational performance and robust cash reserves. Additionally, Electromed expanded access through a partnership in early 2024 aimed at veterans, federal employees, and Native American communities, advancing its mission to broaden patient reach. Electromed continues to focus on airway clearance innovation and market-driven solutions to support patients with chronic lung diseases, driving growth through product development, strategic partnerships, and expanded distribution while maintaining a strong market presence in the healthcare equipment and supplies sector.

Company News

  • Electromed: Contrarian 'Buy' With SmartVest

  • Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript

  • Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates

  • Electromed Announces CEO's Planned Retirement

  • Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results

  • Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026

  • 4 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, FLXS, ELMD & AGX

  • Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why

  • Here's Why Momentum in Electromed (ELMD) Should Keep going

  • Electromed: Strong Margins, Strong Growth, Large Runway

  • Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

  • Best Momentum Stocks to Buy for June 2nd

  • New Strong Buy Stocks for June 2nd

  • Electromed, Inc. (ELMD) Hits Fresh High: Is There Still Room to Run?

  • 3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes

  • Electromed, Inc. (ELMD)'s Technical Outlook is Bright After Key Golden Cross

  • Electromed (ELMD) is an Incredible Growth Stock: 3 Reasons Why

  • What Makes Electromed (ELMD) a Good Fit for 'Trend Investing'

  • 5 High-Efficiency Stocks to Buy Now: HCSG, ELMD, UMBF, SHEL, MTSI

  • All You Need to Know About Electromed (ELMD) Rating Upgrade to Strong Buy